Fibrolamellar Cancer Foundation Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2016
NCT02702960
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now